Visiogen, Inc. Release: Randomized, Controlled, Double-Masked Clinical Trial of Synchrony® Accommodating IOL Demonstrates Positive Impact of True Accommodation on Patient Outcomes

IRVINE, Calif.--(BUSINESS WIRE)--Visiogen, Inc. was well represented at the XXVI Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), held in Berlin from September 13 to 17. Six independent investigators presented clinical results at the meeting, confirming that the physiologic design and proven accommodation mechanism of the Synchrony® IOL is providing patients with sustained positive outcomes and functional vision at all distances.